JP2018502112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502112A5 JP2018502112A5 JP2017534822A JP2017534822A JP2018502112A5 JP 2018502112 A5 JP2018502112 A5 JP 2018502112A5 JP 2017534822 A JP2017534822 A JP 2017534822A JP 2017534822 A JP2017534822 A JP 2017534822A JP 2018502112 A5 JP2018502112 A5 JP 2018502112A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- therapeutic agent
- aav
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462098085P | 2014-12-30 | 2014-12-30 | |
| US62/098,085 | 2014-12-30 | ||
| PCT/US2015/068034 WO2016109649A1 (en) | 2014-12-30 | 2015-12-30 | Methods and compositions for treating brain diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502112A JP2018502112A (ja) | 2018-01-25 |
| JP2018502112A5 true JP2018502112A5 (OSRAM) | 2019-02-07 |
| JP6782701B2 JP6782701B2 (ja) | 2020-11-11 |
Family
ID=56285031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534822A Active JP6782701B2 (ja) | 2014-12-30 | 2015-12-30 | 脳疾患を処置するための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11612641B2 (OSRAM) |
| EP (1) | EP3240577B1 (OSRAM) |
| JP (1) | JP6782701B2 (OSRAM) |
| KR (1) | KR102618947B1 (OSRAM) |
| CN (1) | CN107405414A (OSRAM) |
| AU (1) | AU2015374043B2 (OSRAM) |
| BR (1) | BR112017013674A2 (OSRAM) |
| CA (1) | CA2971687C (OSRAM) |
| ES (1) | ES2962439T3 (OSRAM) |
| SG (1) | SG11201704829QA (OSRAM) |
| WO (1) | WO2016109649A1 (OSRAM) |
| ZA (1) | ZA201704327B (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112410338A (zh) | 2014-11-14 | 2021-02-26 | 沃雅戈治疗公司 | 调节性多核苷酸 |
| IL292999A (en) | 2014-11-14 | 2022-07-01 | Voyager Therapeutics Inc | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| EP3240577B1 (en) | 2014-12-30 | 2023-07-05 | University of Iowa Research Foundation | Therapeutic agent that activates mtorc1 function for use in treating huntington's disease |
| SG11201809699XA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| KR20220108216A (ko) | 2016-05-18 | 2022-08-02 | 보이저 테라퓨틱스, 인크. | 헌팅톤 질환을 치료하기 위한 조성물 및 방법 |
| CL2016003282A1 (es) * | 2016-12-21 | 2017-08-18 | Univ Chile | Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington |
| WO2018132791A1 (en) | 2017-01-16 | 2018-07-19 | The Regents Of The University Of California | Treatment of neurodegenerative conditions by disruption of rhes |
| JP2020518259A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハンチントン病治療組成物および方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050255086A1 (en) | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
| US20050009112A1 (en) | 2003-03-07 | 2005-01-13 | Fred Hutchinson Cancer Research Center, Office Of Technology Transfer | Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth |
| JP2008539276A (ja) | 2005-04-27 | 2008-11-13 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド | ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法 |
| KR101286870B1 (ko) * | 2009-11-30 | 2013-07-16 | (주)아모레퍼시픽 | 황기 추출물을 포함하는 대사 촉진 조성물 |
| PH12014500912A1 (en) * | 2011-10-28 | 2014-06-09 | Novartis Ag | Novel purine derivatives and their use in the treatment of disease |
| WO2013067125A1 (en) * | 2011-11-01 | 2013-05-10 | Children's Medical Center Corporation | Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration |
| CN106924741A (zh) | 2011-11-08 | 2017-07-07 | 因特利凯有限责任公司 | 使用多种药剂的治疗方案 |
| WO2013116691A1 (en) * | 2012-02-02 | 2013-08-08 | The Washington University | Methods for improving muscle strength |
| KR101626526B1 (ko) | 2014-10-30 | 2016-06-02 | 경북대학교 산학협력단 | ｈＲｈｅｂ를 유효성분으로 포함하는 허혈성 뇌질환의 예방 또는 치료용 조성물 |
| EP3240577B1 (en) | 2014-12-30 | 2023-07-05 | University of Iowa Research Foundation | Therapeutic agent that activates mtorc1 function for use in treating huntington's disease |
-
2015
- 2015-12-30 EP EP15876243.5A patent/EP3240577B1/en active Active
- 2015-12-30 US US15/540,746 patent/US11612641B2/en active Active
- 2015-12-30 CA CA2971687A patent/CA2971687C/en active Active
- 2015-12-30 JP JP2017534822A patent/JP6782701B2/ja active Active
- 2015-12-30 KR KR1020177020915A patent/KR102618947B1/ko active Active
- 2015-12-30 ES ES15876243T patent/ES2962439T3/es active Active
- 2015-12-30 BR BR112017013674A patent/BR112017013674A2/pt not_active Application Discontinuation
- 2015-12-30 SG SG11201704829QA patent/SG11201704829QA/en unknown
- 2015-12-30 CN CN201580077153.9A patent/CN107405414A/zh active Pending
- 2015-12-30 WO PCT/US2015/068034 patent/WO2016109649A1/en not_active Ceased
- 2015-12-30 AU AU2015374043A patent/AU2015374043B2/en active Active
-
2017
- 2017-06-26 ZA ZA2017/04327A patent/ZA201704327B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514286A5 (OSRAM) | ||
| JP2014512171A5 (OSRAM) | ||
| JP2017513504A5 (OSRAM) | ||
| JP2021530548A (ja) | 遺伝子治療製剤を生産するための系および方法 | |
| JP2018520646A5 (OSRAM) | ||
| Ozlu et al. | Gene transfer therapy for neurodevelopmental disorders | |
| JP2019513779A5 (OSRAM) | ||
| JP2019504003A5 (OSRAM) | ||
| JP2015520161A5 (OSRAM) | ||
| BR112017005892A2 (pt) | variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma | |
| RU2021134920A (ru) | Композиции и способы деградации неправильно упакованных белков | |
| PH12021552887A1 (en) | Modified viral particles and uses thereof | |
| JP2018537984A5 (OSRAM) | ||
| JP2020537637A5 (OSRAM) | ||
| JP2014526904A5 (OSRAM) | ||
| EA202091194A1 (ru) | Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки | |
| JP2018509154A5 (OSRAM) | ||
| FI3737423T3 (fi) | Koostumuksia ja menetelmiä verkkokalvon häiriöiden hoitoon | |
| ZA201704327B (en) | Methods and compositions for treating brain diseases | |
| JP2020527167A5 (OSRAM) | ||
| FI3873511T3 (fi) | Ekspressiovektori kolesteroli-24-hydrolaasille amyotroofisen lateraaliskleroosin hoitoon | |
| JP2023542950A (ja) | α－シヌクレインの凝集を阻害するための組成物及び方法 | |
| Duan et al. | Deaths in gene therapy of Duchenne muscular dystrophy and other diseases: underlying mechanisms and mitigating strategies | |
| MX2022004799A (es) | Composiciones y metodos para el tratamiento de los trastornos de almacenamiento de glucogeno. | |
| Ketterl et al. | Ofatumumab for refractory opsoclonus‐myoclonus syndrome following treatment of neuroblastoma |